p53-R280S mutation confers lenvatinib resistance in hepatocellular carcinoma via Bcl-2-mediated anti-apoptotic signaling

Niangmei Cheng, Kexin Liu, Xin Qi, Leijie Cai, Yang Zhou, Fei Wang, Bixing Zhao, Yingchao Wang · 2026

Read p53-R280S mutation confers lenvatinib resistance in hepatocellular carcinoma via Bcl-2-mediated anti-apoptotic signaling by Niangmei Cheng, Kexin Liu, Xin Qi, Leijie Cai, Yang Zhou, Fei Wang, Bixing Zhao, Yingchao Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13638713.txt.

Description

Niangmei Cheng and seven colleagues published a 2026 laboratory study on why liver cancer can stop responding to the drug lenvatinib. That drug is a first-line treatment for liver cancer that cannot be removed by surgery, but resistance often develops over time.

Sequencing of resistant cancer cells pointed to a change in the p53 gene called R280S. Cells carrying that change survived lenvatinib better in dishes and in mouse tumors, partly because the altered protein raised Bcl-2, a protein that blocks cell death, and lowered BAX. The work names one route to resistance that future drugs might try to close.

Catalog record

CREATORNiangmei Cheng, Kexin Liu, Xin Qi, Leijie Cai, Yang Zhou, Fei Wang, Bixing Zhao, Yingchao Wang
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35268
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13638713

Browse the full library · About the Tower of Babel